Per the 2017 NCCN guidelines, high dose interleukin-2 (HD IL2) therapy for metastatic melanoma is recommended as second line [2] and recommended as first line for predominant clear cell histology for Stage IV renal cell carcinoma [3]. Here, IL2 is linked to hereditary clear cell renal cell carcinoma.